TMI-1

TMI-1 inhibits TNF-α secretion in mouse monocyte Raw cells with an IC₅₀ of 40 nM, in human monocyte THP-1 cells with an IC₅₀ of 200 nM, in primary human monocyte lines with an IC₅₀ of 190 nM, and in human whole blood with an IC₅₀ of 300 nM^[1].
TMI-1 inhibits the shedding of TNFR II in human whole blood, with an IC₅₀ of 0.72μM^[1].
TMI-1 (0-20 μM, 5 days) shows a dose-dependent inhibition of proliferation in breast cancer cell lines BT-20, SUM149, MDA-MB-231, SK-BR-3, L226, SUM190, T147D and Cama-1, with ED₅₀ of 1.3, 1.5, 8.1, 1.6, 2.0, 2.0, 2.5, and 2.5 μM respectively, and induces the activity of Caspase-3 and Caspase-7 without affecting the vitality of normal cells^[2].
TMI-1 (0-20 μM, 48 h) inhibits the cell cycle of breast cancer cells SUM149, promotes apoptosis, activates Caspase-3, Caspase-7, Caspase-8, Caspase-9, and increases ROS production^[2].
TMI-1 (4 ng/mL, 24 h) improves the degenerative changes in the axons of 50B11 cells induced by paclitaxel (HY-B0015) and enhances the growth of neurites induced by forskolin (HY-15371), and this effect is dose-dependent^[3].
TMI-1 (0.04-4 ng/mL, 24 h) reduces the expression of TRPV1 protein in 50B11 cells in a dose-dependent manner, along with a decrease in the expressions of PKC, PI3K, NF-κB, TNF-α, IL-1β, and IL-6 mRNA, as well as calcium influx^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.